Lutetium-177 (Pluvicto) vs. PSMA-Actinium | #MarkScholzMD #AlexScholz #PCRI
Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRISee more
PSMA & Lutetium-177 in 2022 | Eugene Kwon, MD | DIY Combat Manual for Beating Prostate Cancer Part 4See more
Managing Terminal Prostate Cancer | #MarkScholzMD #AlexScholz #PCRISee more
New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRISee more
Lutetium-177 PSMA therapySee more
PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022See more
TheraP: cabazitaxel versus 177Lu-PSMA-617 for mCRPCSee more
Lutetium-177 and Bipolar Androgen Therapy: Future Game Changers In Prostate Cancer | PCRISee more
Using Lutetium-177 Treatment For Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MDSee more
Limitations of Lutetium-177-PSMA & Addressing Treatment ChallengesSee more
PSMA Targeting for Treatment of Advanced Prostate Cancer - 2021 Prostate Cancer Patient ConferenceSee more
UpFrontPSMA trial: 177Lu-PSMA-617 and docetaxel in mHNPCSee more
Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPCSee more
Efficacy of Lutetium-177–PSMA-617 for Advanced Prostate CancerSee more
VISION: Lu-177-PSMA-617 in mCRPCSee more
An Update on Lutetium-177 for Prostate Cancer | Thomas Hope, MD & Mark Moyad, MD, MPH | 2021 PCRISee more
Safety and Efficacy of 177Lu-PSMA-617See more
Lutetium-177, Radiation For Urinary Flow, ProstRcision, & Ice For Chemo Side Effect | PCRI #12See more
VISION: tolerability of 177Lu-PSMA-617 by treatment exposure in patients with mCRPCSee more
